Cart
sales@molnova.com
CCC07-01
CAS No. 2215102-35-3
CCC07-01( CCC 07-01 | CCC 0701 )
Catalog No. M13531 CAS No. 2215102-35-3
CCC07-01 (CCC 0701) is a novel alkylating compound that is capable of disrupting expression of PD-1, PD-L1 and CTLA-4 genes with IC50 of 15, 10 and 5 nM in cell-base assays.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCCC07-01
-
NoteResearch use only, not for human use.
-
Brief DescriptionCCC07-01 (CCC 0701) is a novel alkylating compound that is capable of disrupting expression of PD-1, PD-L1 and CTLA-4 genes with IC50 of 15, 10 and 5 nM in cell-base assays.
-
DescriptionCCC07-01 (CCC 0701) is a novel alkylating compound that is capable of disrupting expression of PD-1, PD-L1 and CTLA-4 genes with IC50 of 15, 10 and 5 nM in cell-base assays; significantly suppresses PD-1, PD-L1 and CTLA-4 mRNA levels in several cell lines, CCC07-01 is sufficiently lipophilic that enhaced the inhibitory effect of CD94-NKG-2A receptor expressed on subsets of NK cells γδ and CD8+ T cells.
-
In Vitro——
-
In Vivo——
-
SynonymsCCC 07-01 | CCC 0701
-
PathwayImmunology/Inflammation
-
TargetPD-1/PD-L1
-
RecptorPD-1/PD-L1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2215102-35-3
-
Formula Weight1886.378
-
Molecular FormulaC90H93ClN30O16
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. US Patent WO 2018056361.
2. Horiki Nagase, et al. 2018 AACR #2711: Development of a new innovative multifunctional immune checkpoint inhibitor.
molnova catalog
related products
-
BMS-242
A potent PD-1/PD-L1 interaction inhibitor with IC50 of 6-100 nM in a homogenous time-resolved fluorescence binding assay.
-
IMMH 010 maleate
IMMH 010 maleate (YPD-30 maleate) is an orally available programmed cell death ligand 1 inhibitor with potential antitumor activity for the study of neurological disorders and advanced malignant solid tumors.
-
BMS-8
BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers.
